SMAD3 and diabetic kidney disease: The seldom reports of C3aR antagonist treatment in Type II diabetic rats ameliorating diabetic nephropathy hold discrepancies as to the observed effect being due to the suppression of the TGF-β/Smad3 pathway [51], which is inconsistent with our results.